Title Source Documents Date


Second Quarter 2014 Financial Results

Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy

View Presentation

Investor Call Feb 2018

Argos Obtains Option to License PD1 Checkpoint Inhibitors

Argos Announces One-for-Twenty Reverse Stock Split

Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd.

Argos Provides Financial Update

Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.